RxDoctor Payments Data

Elliott Bettman, MD

Internal Medicine · Conway, SCNPI 1144325804

Payments from drug & device makers

$3,021in general payments, 2019–2025

Across 99 payments — averaging $30.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$967
  • AbbVie$604
  • GSK$305
  • Amgen$228
  • Pfizer$213
  • Lilly USA, LLC$140
  • plus $564 from 10 others

What the payments were for

  • Food & beverage$3,00099%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,021 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$28,144
Medicare patients
61
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,739
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl60$8,688
EliquisApixaban12$6,787
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen455$4,057
Albuterol Sulfate HfaAlbuterol Sulfate55$2,443
Tizanidine Hcl51$2,267
Gabapentin198$1,213
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine55$1,069
Pregabalin63$934
Ibuprofen64$854
Promethazine Hcl41$605
Ventolin HfaAlbuterol Sulfate11$601
Buspirone Hcl23$558
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen35$457
Atorvastatin Calcium59$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$305$18,73928 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$34$8,68860 claims
PfizerEliquis$213$6,78712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Conway

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →